Short answer
Celcuity Inc. (CELC) filed an 8-K current report with the SEC on October 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 8 to 9 directors, adding David W. Gryska through the 2027 Annual Meeting.
Celcuity Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 8 to 9 directors, adding David W. Gryska through the 2027 Annual Meeting
- Gryska qualifies as Nasdaq and SEC independent director
- Audit Committee and Compensation Committee appointments strengthen oversight capacity
- Compensation includes $70,000 annual cash retainer and $100,000 annual equity award
- Granted 893 restricted stock units, fully vesting at the earlier of the 2027 Annual Meeting or April 30, 2027
Item 7.01 · Regulation FD Disclosure
- Board appointment announcement for Mr. Gryska, adding a new director to Celcuity’s governance structure
- Audit Committee and Compensation Committee assignments, expanding his oversight responsibilities
- Leadership change potentially relevant to governance, financial reporting oversight and executive compensation decisions
Item EX-99.1 · Exhibit EX-99.1
- David Gryska appointed to Celcuity’s Board, adding over 35 years of life sciences strategic and financial leadership
- Former CFO of Incyte and Celgene, strengthening oversight as Celcuity transitions to commercial operations
- Appointment follows FDA approval and planned commercial launch of REVTORPYK in advanced breast cancer
- Board expertise supports REVTORPYK commercialization and gedatolisib development across breast and prostate cancer indications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celcuity Inc. 8-K filings
Get the next CELC 8-K as it lands
Follow CELC for push alerts, or ask the research agent what this filing means.